Filling in the Treatment Gap for Patients With EGFR+ NSCLC
Xiuning Le, MD, PhD, discusses the limited treatment options available for patients with non–small cell lung cancer and an EGFR exon 20 mutation.
Xiuning Le, MD, PhD, assistant professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center in Houston, Texas discusses the limited treatment options available for patients with non–small cell lung cancer (NSCLC) and an EGFR exon 20 mutation.
There is currently no FDA approved agent to treat patients with EGFR or HER2 exon 20-positive NSCLC. Targeting these oncogenes is a great unmet medical need, explains Le, and although chemotherapy is still an option to treat patients with EGFR-positive NSCLC, it is important use all the tools that are available to treat this patient population.
Introducing a small molecule tyrosine kinase inhibitor such as poziotinib is important for the future treatment of EGFR and HER exon 20-positive NSCLC. The hope is to bring more options to field.
FDA Grants Breakthrough Therapy Designation to Sunvozertinib in EGFR Exon20+ NSCLC
April 9th 2024Sunvozertinib was granted breakthrough therapy designation by the FDA for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation.
Read More
Amivantamab/Lazertinib Still Effective in EGFRm NSCLC Despite Dose Interruptions
March 26th 2024According to a subset analysis of the phase 3 MARIPOSA trial, dose interruptions during the course of amivantamab and lazertinib treatment were still effective in EGFR-mutant non-small cell lung cancer.
Read More
Osimertinib Enhances Progression-Free Survival in Stage III NSCLC
February 19th 2024Osimertinib shows significant progression-free survival improvement in stage III EGFR-mutated non-small cell lung cancer post-chemoradiotherapy, marking a major advance in treatment options for this patient population.
Read More
